Status:
COMPLETED
The Effects of DHA on Attention Deficit and Hyperactivity Disorder
Lead Sponsor:
IRCCS Eugenio Medea
Collaborating Sponsors:
DMF srl (Dietetic Metabolic Food)
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
6-14 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether docosahexaenoic acid (DHA) is effective in reducing Attention Deficit/Hyperactivity Disorder (ADHD) core symptoms in a clinical sample of children and...
Detailed Description
The primary objective of this study is to investigate the relative efficacy and tolerability of omega-3 fatty acid supplementation, more specifically docosahexaenoic acid (DHA), in reducing attention-...
Eligibility Criteria
Inclusion
- Clinical diagnosis of ADHD based on DSM-IV criteria and confirmed with Development and Well-Being Assessment (DAWBA) interview
- Comorbid disorder accepted: mood disorder, anxiety disorder, oppositional defiant disorder, conduct disorder, learning disorder
- Total IQ equal or above 85
- Aged from 6 to 14 years
Exclusion
- Autism, Schizophrenia or othe psychiatric disorder not included in inclusion criteria
- associated neurologic, genetic, infectious or metabolic disorder, or a seizure disorder
- present or past use of any psychoactive drugs
Key Trial Info
Start Date :
June 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01796262
Start Date
June 1 2012
End Date
June 1 2015
Last Update
February 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Eugenio Medea
Bosisio Parini, Lecco, Italy, 23842